Detailed Information on Publication Record
2021
Enhancing cisplatin anticancer effectivity and migrastatic potential by modulation of molecular weight of oxidized dextran carrier
MUNSTER, L., Michaela FOJTŮ, M. MUCHOVA, F. LATECKA, S. KACEROVA et. al.Basic information
Original name
Enhancing cisplatin anticancer effectivity and migrastatic potential by modulation of molecular weight of oxidized dextran carrier
Authors
MUNSTER, L., Michaela FOJTŮ (203 Czech Republic, belonging to the institution), M. MUCHOVA (203 Czech Republic), F. LATECKA (203 Czech Republic), S. KACEROVA (203 Czech Republic), Z. CAPAKOVA (203 Czech Republic), Tamara JURIŇÁKOVÁ (703 Slovakia, belonging to the institution), I. KURITKA (203 Czech Republic), Michal MASAŘÍK (203 Czech Republic, belonging to the institution) and J. VICHA (203 Czech Republic, guarantor)
Edition
Carbohydrate Polymers, Oxford, ELSEVIER SCI LTD, 2021, 0144-8617
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
10401 Organic chemistry
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 10.723
RIV identification code
RIV/00216224:14110/21:00119604
Organization unit
Faculty of Medicine
UT WoS
000689229600012
Keywords in English
Drug-delivery; Dextran; Periodate oxidation; Molecular weight; Cisplatin; Carrier
Tags
International impact, Reviewed
Změněno: 24/1/2022 07:55, Mgr. Tereza Miškechová
Abstract
V originále
The molecular weight (M-w) of dextran derivatives, such as regioselectively oxidized dicarboxydextran (DXA), is greatly influencing their faith in an organism, which could be possibly used to improve anticancer drug delivery. Here we present a modified method of sulfonation-induced chain scission allowing direct and accurate control over the M-w of DXA without increasing its polydispersity. Prepared DXA derivatives (M-w = 10-185 kDa) have been conjugated to cisplatin and the M-w of the carrier found to have a significant impact on cisplatin release rates, in vitro cytotoxicity, and migrastatic potential. Conjugates with the high-M-w DXA showed particularly increased anticancer efficacy. The best conjugate was four times more effective against malignant prostatic cell lines than free cisplatin and significantly inhibited the ovarian cancer cell migration. This was traced to the characteristics of spontaneously formed cisplatin-crosslinked DXA nanogels influenced by M-w of DXA and amount of loaded cisplatin.
Links
GA19-16861S, research and development project |
| ||
LM2018127, research and development project |
| ||
MUNI/A/1246/2020, interní kód MU |
| ||
MUNI/A/1698/2020, interní kód MU |
| ||
MUNI/11/SUP/08/2020, interní kód MU |
|